Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Ferriprox“
Suchtreffer
Begriffe & Kennungen
Ferriprox · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenFerriprox · 4.8 · Some patients experienced progression of fibrosis associated with an increase in iron overload or hepatitis C.
Eintrag öffnenFerriprox · 4.8 · Some patients experienced progression of fibrosis associated with an increase in iron overload or hepatitis C.
Eintrag öffnenFerriprox · 4.8 · Summary of the safety profile
Eintrag öffnenFerriprox · 4.8 · Summary of the safety profile
Eintrag öffnenFerriprox · 4.8 · System organ class Very common Common Frequency not (≥ 1/10) (≥ 1/100 to < 1/10) known Blood and lymphatic sys
Eintrag öffnenFerriprox · 4.8 · System organ class Very common Common Frequency not (≥ 1/10) (≥ 1/100 to < 1/10) known Blood and lymphatic sys
Eintrag öffnenFerriprox · 4.8 · Table 2: List of adverse reactions
Eintrag öffnenFerriprox · 4.8 · Table 2: List of adverse reactions
Eintrag öffnenFerriprox · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenFerriprox · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenFerriprox · 4.8 · The incidences of adverse reactions experienced by 18 children and 97 adults treated with combination therapy
Eintrag öffnenFerriprox · 4.8 · The most common adverse reactions reported during therapy with deferiprone in clinical studies were nausea, vo
Eintrag öffnenFerriprox · 4.8 · The most common adverse reactions reported during therapy with deferiprone in clinical studies were nausea, vo
Eintrag öffnenFerriprox · 4.8 · The most serious adverse reaction reported in clinical studies with deferiprone is agranulocytosis (neutrophil
Eintrag öffnenFerriprox · 4.8 · The most serious adverse reaction reported in clinical studies with deferiprone is agranulocytosis (neutrophil
Eintrag öffnenFerriprox · 4.8 · The observed incidence of the less severe form of neutropenia (neutrophils < 1.5x109/l) is 4.9% (2.5 cases per
Eintrag öffnenFerriprox · 4.8 · The observed incidence of the less severe form of neutropenia (neutrophils < 1.5x109/l) is 4.9% (2.5 cases per
Eintrag öffnenFerriprox · 4.8 · The safety profile of combination therapy (deferiprone and deferoxamine) observed in clinical studies, post-ma
Eintrag öffnenFerriprox · 4.8 · The safety profile of combination therapy (deferiprone and deferoxamine) observed in clinical studies, post-ma
Eintrag öffnen